On April 1, 2024, Astrazeneca announced the FDA approval of its "first-in-class" oral small molecule Voydeya (danicopan). As an addition to the standard therapy complement factor C5 inhibitors Ultomiris (ravulizumab) or Soliris (eculizumab) for the treatment of extravascular hemolysis (EVH) in adult patients with parsmal sleep hemogalbuminuria (PNH)

Next: Nature Biotechnology | Antibody Drug Conjugators (ADCs) : ushering in a new era of precision cancer therapy